Johnson & Johnson (NYSE: JNJ) announces it has entered into a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink™ DAC platform for KRAS-driven tumors bolsters Johnson & Johnson’s oncology pipeline and ambition to develop targeted medicines for the most prevalent and hard-to-treat solid tumors with high unmet need. The Firelink™ DAC platform is a novel, innovative approach to overcome limitations of existing treatments by delivering a highly selective protein degrader to tumor cells, while avoiding healthy cells.
Read the full article: Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform //
Source: https://www.businesswire.com/news/home/20260608808565/en/Johnson-Johnson-to-Acquire-Firefly-Bio-Inc.-to-Expand-Oncology-Pipeline-with-Novel-Degrader-Antibody-Conjugate-Platform